BARDA invests in a self-amplifying mRNA vaccine for Influenza

Arcturus Therapeutics obtained a 63 million-dollar grant from the Biomedical Advanced Research and Development Authority (better known as the government program, BARDA). This will support the development of a self-amplifying mRNA vaccine for influenza.
The award provides the funding over three years to support preclinical, manufacturing, nonclinical safety studies, along with development and regulatory support for Arcturus’ vaccine platform technology through Phase 1 clinical studies.